| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006.
|
Ann Oncol
|
2007
|
2.05
|
|
2
|
Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial.
|
Ann Oncol
|
2008
|
1.66
|
|
3
|
Oesophageal cancer treatment: studies, strategies and facts.
|
Ann Oncol
|
1998
|
1.53
|
|
4
|
Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trial.
|
Ann Oncol
|
2011
|
1.49
|
|
5
|
Prognosis and adjuvant treatment effects in selected breast cancer subtypes of very young women (<35 years) with operable breast cancer.
|
Ann Oncol
|
2010
|
1.47
|
|
6
|
Treatment of advanced breast cancer: the good, the bad and the ugly.
|
Ann Oncol
|
2005
|
1.42
|
|
7
|
Bone scan had no role in the staging of 765 consecutive operable T(1-2)N(0-1) breast cancer patients without skeletal symptoms.
|
Ann Oncol
|
2001
|
1.41
|
|
8
|
Depression and degree of acceptance of adjuvant cytotoxic drugs.
|
Lancet
|
2000
|
1.39
|
|
9
|
Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial.
|
Ann Oncol
|
2009
|
1.26
|
|
10
|
Guidelines on the standards for the training of specialised health professionals dealing with breast cancer.
|
Eur J Cancer
|
2007
|
1.20
|
|
11
|
Progesterone receptor loss identifies Luminal B breast cancer subgroups at higher risk of relapse.
|
Ann Oncol
|
2012
|
1.19
|
|
12
|
The inhibition of monoacylglycerol lipase by URB602 showed an anti-inflammatory and anti-nociceptive effect in a murine model of acute inflammation.
|
Br J Pharmacol
|
2007
|
1.18
|
|
13
|
Prognosis in women with small (T1mic,T1a,T1b) node-negative operable breast cancer by immunohistochemically selected subtypes.
|
Breast Cancer Res Treat
|
2011
|
1.12
|
|
14
|
Systemic treatments for women with breast cancer: outcome with relation to screening for the disease.
|
Ann Oncol
|
2003
|
1.07
|
|
15
|
Preoperative bevacizumab combined with letrozole and chemotherapy in locally advanced ER- and/or PgR-positive breast cancer: clinical and biological activity.
|
Br J Cancer
|
2008
|
1.02
|
|
16
|
SR 141716A, a cannabinoid receptor antagonist, reverses the behavioural effects of anandamide-treated rats.
|
Behav Pharmacol
|
1999
|
1.01
|
|
17
|
Repeated treatment with the synthetic cannabinoid WIN 55,212-2 reduces both hyperalgesia and production of pronociceptive mediators in a rat model of neuropathic pain.
|
Br J Pharmacol
|
2003
|
1.00
|
|
18
|
Breast cancer subtypes and outcome after local and regional relapse.
|
Ann Oncol
|
2011
|
0.98
|
|
19
|
Adding adjuvant CMF chemotherapy to either radiotherapy or tamoxifen: are all CMFs alike? The International Breast Cancer Study Group (IBCSG).
|
Ann Oncol
|
1998
|
0.95
|
|
20
|
CA15-3 and alkaline phosphatase as predictors for breast cancer recurrence: a combined analysis of seven International Breast Cancer Study Group trials.
|
Ann Oncol
|
2007
|
0.94
|
|
21
|
Intrapericardial treatment of neoplastic pericardial effusions.
|
Herz
|
2000
|
0.94
|
|
22
|
Breast cancer in Hodgkin's disease and non-Hodgkin's lymphoma survivors.
|
Ann Oncol
|
2006
|
0.93
|
|
23
|
Recognizing features that are dissimilar in male and female breast cancer: expression of p21Waf1 and p27Kip1 using an immunohistochemical assay.
|
Ann Oncol
|
2002
|
0.92
|
|
24
|
Prognostic value of Ki-67 labeling index in patients with node-negative, triple-negative breast cancer.
|
Breast Cancer Res Treat
|
2012
|
0.92
|
|
25
|
Radiotherapy and chemotherapy in high-risk breast cancer.
|
N Engl J Med
|
1998
|
0.91
|
|
26
|
Long-term results of International Breast Cancer Study Group Trial VIII: adjuvant chemotherapy plus goserelin compared with either therapy alone for premenopausal patients with node-negative breast cancer.
|
Ann Oncol
|
2011
|
0.90
|
|
27
|
Mortality during adjuvant treatment of early breast cancer with cyclophosphamide, methotrexate, and fluorouracil. International Breast Cancer Study Group.
|
Lancet
|
1999
|
0.88
|
|
28
|
Are all high-grade breast cancers with no steroid receptor hormone expression alike? The special case of the medullary phenotype.
|
Ann Oncol
|
2005
|
0.88
|
|
29
|
HER2-negative (1+) breast cancer with unfavorable prognostic features: to FISH or not to FISH?
|
Ann Oncol
|
2012
|
0.88
|
|
30
|
Cross-tolerance and convergent dependence between morphine and cannabimimetic agent WIN 55,212-2 in the guinea-pig ileum myenteric plexus.
|
Eur J Pharmacol
|
1999
|
0.88
|
|
31
|
Management of advanced breast cancer.
|
Ann Oncol
|
2007
|
0.88
|
|
32
|
Prognostic role of CA15.3 in 7942 patients with operable breast cancer.
|
Breast Cancer Res Treat
|
2011
|
0.87
|
|
33
|
Endocrine therapy of breast cancer.
|
Ann Oncol
|
2002
|
0.87
|
|
34
|
Symptoms of endocrine treatment and outcome in the BIG 1-98 study.
|
Breast Cancer Res Treat
|
2013
|
0.86
|
|
35
|
Loss of cannabinoid-stimulated guanosine 5'-O-(3-[(35)S]Thiotriphosphate) binding without receptor down-regulation in brain regions of anandamide-tolerant rats.
|
J Neurochem
|
2000
|
0.86
|
|
36
|
Nitroxide TEMPOL impairs mitochondrial function and induces apoptosis in HL60 cells.
|
J Cell Biochem
|
2001
|
0.85
|
|
37
|
Factor V Leiden and G20210A prothrombin mutation and the risk of subclavian vein thrombosis in patients with breast cancer and a central venous catheter.
|
Ann Oncol
|
2004
|
0.85
|
|
38
|
Precipitated and spontaneous withdrawal in rats tolerant to anandamide.
|
Psychopharmacology (Berl)
|
2000
|
0.85
|
|
39
|
Antitumour and biological effects of letrozole and GnRH analogue as primary therapy in premenopausal women with ER and PgR positive locally advanced operable breast cancer.
|
Br J Cancer
|
2007
|
0.84
|
|
40
|
Vinorelbine, cisplatin and continuous infusion of 5-fluorouracil (ViFuP) in metastatic breast cancer patients: a phase II study.
|
Ann Oncol
|
2001
|
0.84
|
|
41
|
ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of locally recurrent or metastatic breast cancer (MBC).
|
Ann Oncol
|
2005
|
0.83
|
|
42
|
Adjuvant chemoendocrine therapy in postmenopausal breast cancer: cyclophosphamide, methotrexate, and fluorouracil dose and schedule may make a difference. International Breast Cancer Study Group.
|
J Clin Oncol
|
1998
|
0.83
|
|
43
|
Changes in rat brain energetic metabolism after exposure to anandamide or Delta(9)-tetrahydrocannabinol.
|
Eur J Pharmacol
|
2000
|
0.83
|
|
44
|
Detection by denaturant gradient gel electrophoresis of tumor-specific mutations in biopsies and relative bronchoalveolar lavage fluid from resectable non-small cell lung cancer.
|
Clin Cancer Res
|
2000
|
0.82
|
|
45
|
Systemic effects of surgery: quantitative analysis of circulating basic fibroblast growth factor (bFGF), Vascular endothelial growth factor (VEGF) and transforming growth factor beta (TGF-beta) in patients with breast cancer who underwent limited or extended surgery.
|
Breast Cancer Res Treat
|
2005
|
0.82
|
|
46
|
Second Axillary Sentinel Lymph Node Biopsy for Breast Tumor Recurrence: Experience of the European Institute of Oncology.
|
Ann Surg Oncol
|
2014
|
0.81
|
|
47
|
Minimal axillary lymph node involvement in breast cancer has different prognostic implications according to the staging procedure.
|
Breast Cancer Res Treat
|
2009
|
0.81
|
|
48
|
Adjuvant chemotherapy for cancer of gastrointestinal tract: a critical review.
|
Tumori
|
1992
|
0.80
|
|
49
|
Primary systemic therapy on local advance breast cancer, where are we going?
|
Ann Oncol
|
2006
|
0.80
|
|
50
|
Doxifluridine and leucovorin: an oral treatment combination in advanced colorectal cancer.
|
J Clin Oncol
|
1995
|
0.80
|
|
51
|
Reply to the article "Metronomic therapy with cyclophosphamide induces rat lymphoma and sarcoma regression, and is devoid of toxicity" by V. R. Rozados et al. (Ann Oncol 2004; 15: 1543-1550): ... and in humans?
|
Ann Oncol
|
2005
|
0.80
|
|
52
|
Primary chemotherapy in operable breast cancer with favorable prognostic factors: a pilot study evaluating the efficacy of a regimen with a low subjective toxic burden containing vinorelbine, 5-fluorouracil and folinic acid (FLN).
|
Ann Oncol
|
1999
|
0.80
|
|
53
|
Adverse prognostic value of peritumoral vascular invasion: is it abrogated by adequate endocrine adjuvant therapy? Results from two International Breast Cancer Study Group randomized trials of chemoendocrine adjuvant therapy for early breast cancer.
|
Ann Oncol
|
2009
|
0.80
|
|
54
|
Receptor status (ER, PgR and HER2) discordance between primary tumor and locoregional recurrence in breast cancer.
|
Ann Oncol
|
2011
|
0.79
|
|
55
|
Mitochondrial toxicity of iron and the protective role of ferritin on dopaminergic PC12 cell line.
|
Toxicol In Vitro
|
1995
|
0.79
|
|
56
|
Chemotherapy with vinorelbine, cisplatin and continuous infusion of 5-fluorouracil in locally advanced breast cancer: a promising low-toxic regimen.
|
Anticancer Res
|
2002
|
0.79
|
|
57
|
SR141716A induces in rats a behavioral pattern opposite to that of CB1 receptor agonists.
|
Zhongguo Yao Li Xue Bao
|
1999
|
0.78
|
|
58
|
Incidence of venous thromboembolism in breast cancer patients during chemotherapy with vinorelbine, cisplatin, 5-fluorouracil as continuous infusion (ViFuP regimen): is prophylaxis required?
|
Ann Oncol
|
2000
|
0.78
|
|
59
|
Evaluation of Ki-67 expression as a prognostic feature in hepatocellular carcinoma in cirrhosis.
|
Eur J Cancer
|
1995
|
0.78
|
|
60
|
Quality of life and quality-adjusted survival (Q-TWiST) in patients receiving dose-intensive or standard dose chemotherapy for high-risk primary breast cancer.
|
Br J Cancer
|
2007
|
0.78
|
|
61
|
Factors that predict early treatment failure for patients with locally advanced (T4) breast cancer.
|
Br J Cancer
|
2008
|
0.78
|
|
62
|
Prospective randomised trial comparing fluorouracil versus doxifluridine for the treatment of advanced colorectal cancer.
|
Eur J Cancer
|
1993
|
0.77
|
|
63
|
Classic Kaposi's sarcoma: a review of 90 cases.
|
J Dermatol
|
1992
|
0.77
|
|
64
|
Cerebral extract from morphine-tolerant rats shows antiopiate properties in guinea pig ileum bioassay.
|
Pharmacol Res Commun
|
1988
|
0.77
|
|
65
|
Goserelin in premenopausal advanced breast cancer: clinical and endocrine evaluation of responsive patients.
|
Oncology
|
1994
|
0.77
|
|
66
|
Fluorouracil plus folinic acid in metastatic adenocarcinoma of unknown primary site suggestive of a gastrointestinal primary.
|
Tumori
|
1993
|
0.77
|
|
67
|
Changes in catalase, glutathione peroxidase and glutathione-S-transferase activities in the liver of newts exposed to 2-methyl-4-chlorophenoxyacetic acid (MCPA).
|
Pharmacol Toxicol
|
1989
|
0.76
|
|
68
|
PPADS, a purinergic antagonist reduces Fos expression at spinal cord level in a mouse model of mononeuropathy.
|
Brain Res
|
2008
|
0.76
|
|
69
|
Can tamoxifen relieve motion sickness?
|
Ann Oncol
|
2005
|
0.76
|
|
70
|
Hepatic intra-arterial chemotherapy using a percutaneous catheter in pretreated patients with metastatic colorectal carcinoma.
|
Anticancer Res
|
2004
|
0.76
|
|
71
|
Adjuvant treatment for young women with early breast cancer.
|
Minerva Ginecol
|
2007
|
0.76
|
|
72
|
[Huber needle in situ inpatients under continuous infusion chemotherapy: results of a study, Phase II].
|
Prof Inferm
|
2001
|
0.75
|
|
73
|
Lapatinib and metronomic capecitabine combination in an HER2-positive inflammatory breast cancer patient: a case report.
|
Ann Oncol
|
2009
|
0.75
|
|
74
|
Medical treatment of hepatocarcinoma.
|
Ital J Gastroenterol
|
1992
|
0.75
|
|
75
|
Further investigations on serum ultrafiltrate as medium for tissue respiration in vitro.
|
Dev Biol Stand
|
1985
|
0.75
|
|
76
|
Systemic treatment of advanced malignant-melanoma (review).
|
Int J Oncol
|
1993
|
0.75
|
|
77
|
Weekly carboplatin in elderly patients with advanced ovarian cancer.
|
Oncol Rep
|
1996
|
0.75
|
|
78
|
Chronic cannabinoid, CP-55,940, administration alters biotransformation in the rat.
|
Eur J Pharmacol
|
1996
|
0.75
|
|
79
|
Breast cancer at the end of a successful century: meeting highlights from the First Milan Breast Cancer Conference and discussion paper for the Second Conference (Milan, 14-16 June, 2000).
|
Breast
|
2000
|
0.75
|
|
80
|
Chemotherapy of advanced malignant-melanoma (review).
|
Oncol Rep
|
1994
|
0.75
|
|
81
|
Feasibility of paclitaxel in a patient with anthracycline-induced congestive heart failure.
|
Eur J Cancer
|
1997
|
0.75
|
|
82
|
Hepatic toxicity from cyclophosphamide, methotrexate, fluorouracil (CMF regimen)
|
Ann Oncol
|
1999
|
0.75
|
|
83
|
Evidence of responsiveness to chemotherapy in aggressive Rosai-Dorfman disease.
|
Eur J Cancer
|
1995
|
0.75
|
|
84
|
Home treatment with interleukin 2 and beta-interferon in patients with colorectal cancer and hepatocellular carcinoma.
|
Oncology
|
1994
|
0.75
|
|
85
|
A phase II study of primary dose-dense sequential doxorubicin plus cyclophosphamide and docetaxel in cT4 breast cancer.
|
Anticancer Res
|
2006
|
0.75
|
|
86
|
Recombinant-human-erythropoietin (rhuepo) in the treatment of anemia associated with solid tumors with or without bone-marrow infiltration.
|
Int J Oncol
|
1993
|
0.75
|
|
87
|
Carboplatin and vinorelbine in elderly patients with non-small cell lung cancer.
|
Oncol Rep
|
1996
|
0.75
|
|
88
|
Effective salvage chemotherapy in relapsed or refractory non-Hodgkin's lymphoma.
|
Ann Oncol
|
1993
|
0.75
|
|
89
|
Results of a salvage regimen in refractory or relapsed non-Hodgkin's lymphoma.
|
Leuk Lymphoma
|
1994
|
0.75
|
|
90
|
A randomized phase II trial of two different schedules of mitomycin C and vinorelbine in pretreated breast cancer.
|
Oncology
|
1997
|
0.75
|
|
91
|
Effects of 2-methyl-4-chlorophenoxyacetic acid on the catalase liver activity of chicken embryos.
|
Bull Environ Contam Toxicol
|
1988
|
0.75
|
|
92
|
[Antibody response in cultures of lymphocytes from patients with Hodgkin's lymphoma: role of monocytes].
|
Boll Ist Sieroter Milan
|
1987
|
0.75
|
|
93
|
Pharmacokinetics of oral doxifluridine in patients with colorectal cancer.
|
Tumori
|
1999
|
0.75
|
|
94
|
Lesson learned from high-dose chemotherapy for high-risk breast cancer (What you see is what you mean).
|
Ann Oncol
|
2004
|
0.75
|
|
95
|
Oral chemotherapy with doxifluridine and folinic acid in biliary tract cancer.
|
Eur J Cancer
|
1995
|
0.75
|
|
96
|
Subcutaneous low-dose interleukin-2 plus alpha interferon in advanced malignant melanoma.
|
Tumori
|
1993
|
0.75
|
|
97
|
Role of fluorodeoxyglucose positron emission tomography in the staging of patients with breast cancer candidated to surgery.
|
Ann Oncol
|
2006
|
0.75
|
|
98
|
Assessment of response in primary chemotherapy for breast cancer.
|
Ann Oncol
|
1998
|
0.75
|